entertainment -WSS

entertainment

author：explore 2025-09-28 02:32:23 - browse：665

Adobe

WASHINGTON — WuXi Biologics executives have joined the lobbying fray in the lead-up to a move by Congress to add the company to a blacklist meant to prevent certain biotech firms from doing business in the United States.

Legislation proposing that blacklist, known as the BIOSECURE Act, was passed in a 40-1 bipartisan vote on Wednesday by the House Oversight and Accountability Committee. That’s an important development because until now, the House Select Committee on the Chinese Communist Party had handled the bill in the House. That panel is an ad-hoc committee created to build bipartisan consensus on China policies, but it does not have the authority to pass legislation. A Senate committee also passed the BIOSECURE Act nearly unanimously earlier this year.

With the bill out of the Oversight Committee, the goal is for the House to pass it before the July 4 recess. That would set the legislation up to be included in a year-end must-pass legislative package, possibly the National Defense Authorization Act, which Congress has passed every year for decades.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily intelligence on Capitol Hill and the life sciences industry — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： BioMarin wins approval for gene therapy to treat hemophilia A
Next article： Generative AI mines health records to identify patients’ social needs

focus

knowledge

WSS

Doulas covered by Medicaid under New York's new plan

Kaiser's Risant Health gobbled up Geisinger. Who is next?

Ionis drug prevents swelling attacks due to hereditary angioedema

Heart disease and mental health: A look at cardiac psychology

BMI, flaws aside, is found to be useful estimate of body fat in youth

Idaho abortion case may prompt more restrictions in other states

leisure time

entertainment

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily intelligence on Capitol Hill and the life sciences industry — by subscribing to STAT+.

hotspot

Apple is now the first public company to be valued at $3 trillion

At ASCO, AstraZeneca reports strong data for breast cancer drug

Walensky prepares to leave CDC — and Congress — behind

Readout LOUD podcast: FTC v. biotech, future of Pfizer and Vertex

Cancer drug shortages should be causing more outrage

Letters to First Opinion on caregivers, digital health, and more

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

Idaho abortion case may prompt more restrictions in other states

Continuity nursing helped my family in our darkest PICU moments

ASCO24: AstraZeneca won cancer’s big meeting. Can it fulfill its $80B ambition?

explore

Readout LOUD podcast: live from JPM 2024

JPM 2024: Verve Therapeutics looks to mainstream genome editing

ASCO: AstraZeneca says CAR

FDA’s Peter Marks seems inclined to back Sarepta’s gene therapy

Woman returns to dialysis after doctors remove transplanted pig kidney

Intellia reports positive results for its CRISPR

focus

focus

knowledge

Wikipedia